Patents by Inventor Christopher D. Cox

Christopher D. Cox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazine Carboxamide Orexin Receptor Antagonists
    Publication number: 20120046289
    Abstract: The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 26, 2009
    Publication date: February 23, 2012
    Inventors: Paul J. Coleman, Christopher D. Cox, Swati P. Mercer, Anthony J. Roecker, John D. Schreier
  • 7-AZA-QUINAZOLINE PDE10 INHIBITORS
    Publication number: 20110319409
    Abstract: The present invention is directed to 7-aza-quinazoline compounds of general structural formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 29, 2011
    Inventors: Christopher D. Cox, Izzat T. Raheem, Broc A. Flores, David B. Whitman
  • 2,5-Disubstituted Morpholine Orexin REceptor Antagonists
    Publication number: 20110312961
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: October 15, 2009
    Publication date: December 22, 2011
    Inventors: Christopher D. Cox, Paul J. Coleman, Broc Flores, John D. Schreier
  • 2,3-Disubstituted Piperidine Orexin Receptor Antagonists
    Publication number: 20110263643
    Abstract: The present invention is directed to 2,3-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 27, 2011
    Inventors: Christopher D. Cox, Broc Flores, John D. Schreier
  • 2,5-Disubstituted Piperidine Orexin Receptor Antagonists
    Publication number: 20110251237
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 13, 2011
    Applicant: MERCK SHARP & DOHME CROP.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
  • Quinolone Neuropeptide S Receptor Antagonists
    Publication number: 20110212946
    Abstract: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
    Type: Application
    Filed: November 3, 2009
    Publication date: September 1, 2011
    Inventors: James C. Barrow, Mark T. Bilodeau, Christopher D. Cox, John C. Hartnett, Nathan R. Kett, Yiwei Li, Peter J. Manley, Jeffrey Melamed, William D. Shipe, B. Wesley Trotter, Amy Zartman
  • Disubstituted Azepan Orexin Receptor Antagonists
    Publication number: 20110207715
    Abstract: The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: August 25, 2011
    Inventors: Christopher D. Cox, Mark E. Fraley, John D. Schreier
  • 2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists
    Publication number: 20110201652
    Abstract: The present invention is directed to 2,4-disubstituted pyrrolidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: August 18, 2011
    Inventors: Christopher D. Cox, Paul J. Coleman, John D. Schreier
  • 2,5-Disubstituted Piperidine Orexin Rceptor Antagonists
    Publication number: 20110201632
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: August 18, 2011
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Izzat T. Raheem, Anthony J. Roecker, John D. Schreier
  • SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20110195957
    Abstract: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 11, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jeffrey M. Bergman, Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Swati P. Mercer, Anthony J. Roecker
  • Substituted diazepan orexin receptor antagonists
    Patent number: 7951797
    Abstract: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: May 31, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox
  • SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20100256121
    Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2008
    Publication date: October 7, 2010
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, Anthony J. Roecker
  • OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20100227848
    Abstract: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 14, 2008
    Publication date: September 9, 2010
    Inventors: Christopher D. Cox, David B. Whitman
  • PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20100168134
    Abstract: The present invention is. directed to pyridyl piperidine compounds of formula (I) which are antagonists of orexin receptors, and which are useful' in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 22, 2008
    Publication date: July 1, 2010
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier
  • Mitotic kinesin inhibitors
    Patent number: 7745639
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: June 29, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, J. Christopher Culberson, George D. Hartman, Brenda J. Mariano, Maricel Torrent
  • Mitotic kinesin inhibitors
    Patent number: 7723365
    Abstract: The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: May 25, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio
  • Prodrugs of mitotic kinesin inhibitors
    Patent number: 7718687
    Abstract: The present invention relates to prodrugs of dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: May 18, 2010
    Assignee: Merck Sharp & Dohme Corp.,
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Mitotic Kinesin Inhibitors
    Patent number: 7666862
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: February 23, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox
  • 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20100029736
    Abstract: The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: July 13, 2007
    Publication date: February 4, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Christopher D. Cox, David B. Whitman, Michael J. Breslin
  • Mitotic kinesin inhibitors
    Patent number: 7638549
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: December 29, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox